The Distinct Natural History, Phenotype Spectrum, Familial Penetrance and Clinical Outcomes in Desmin (DES)-Associated Cardiomyopathy
Abstract Body (Do not enter title and authors here): Background: Pathogenic/likely pathogenic variants (P/LP) in the desmin (DES) gene cause heterogeneous cardiomyopathy and skeletal myopathy phenotypes. Research Questions: Limited data suggest that patients with P/LP DES variants have a high incidence of major adverse cardiac events (MACEs), including cardiac conduction disease requiring pacemaker implantation (CCD-PM), sustained ventricular arrhythmias (VA), and heart failure (HF) events (HF hospitalization, heart transplant, HF-related death). However, small cohort sizes have limited full clinical characterization. Aims: We aimed to describe the natural history, phenotype spectrum, familial penetrance and MACE in patients with P/LP DES variants identified via clinical genetic testing. Methods: We conducted a systematic review and individual patient data meta-analysis of cardiac and skeletal myopathy phenotypes and MACE (CCD-PM, VA and HF events) in patients with P/LP DES variants by retrieving publications from Medline (PubMed) and Embase. Diagnosis of cardiomyopathy or MACE were both considered evidence of cardiac involvement. Results: Out of 4,212 screened records, 72 met inclusion criteria. In total, 230 patients were included (52.6% male, 52.2% probands, median age: 31 years at first evaluation [22.0; 42.8]). Eighty-five (37.0%) patients showed isolated cardiac involvement, 89 (38.7%) cardiac and skeletal muscle involvement, 39 (17.0%) only skeletal muscle involvement, and 17 (7.4%) had neither phenotype. Overall, 130 (56.5%) patients were diagnosed with a cardiomyopathy and 134 (57.4%) patients developed MACE (96 [41.7%] had CCD-PM, 36 [15.7%] sustained VA, and 43 [18.7%] HF events). Familial cardiac disease penetrance was 69.1% (76/110) in relatives with P/LP DES variants. Out of 40 patients who presented with isolated CCD-PM phenotype, 18 (45.0%) were diagnosed with a cardiomyopathy after 6 [2.0; 16.0] years of follow-up. In multivariable analysis, male sex and non-missense variants were associated with higher risk of sustained VA (HR 2.71, p=0.008, and HR 4.62, p<0.001, respectively) and HF events (HR 2.63, p=0.005, and HR 2.79, p=0.015). Conclusions:DES cardiomyopathy demonstrates a distinct natural history, characterized by high familial penetrance and a high MACE burden. Male patients and those carrying non-missense variants are at higher risk for sustained VA events and may benefit from primary preventive ICD implantation even in the absence of severe LV systolic dysfunction.
Asatryan, Babken
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Zimmerman, Stefan
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Calkins, Hugh
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
James, Cynthia
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Barth, Andreas
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Rieder, Marina
( Inselspital, Bern University Hospital, University of Bern
, Bern
, Switzerland
)
Muller, Steven
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Murray, Brittney
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Tichnell, Crystal
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Gasperetti, Alessio
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Carrick, Richard
( Johns Hopkins University School of Medicine
, Baltimore
, Maryland
, United States
)
Te Riele, Anneline
( UNIVERSITY MEDICAL CENTER UTRECHT
, Utrecht
, Netherlands
)
Joseph, Emily
( Johns Hopkins University
, Baltimore
, Maryland
, United States
)
Author Disclosures:
Babken Asatryan:DO NOT have relevant financial relationships
| Stefan Zimmerman:DO NOT have relevant financial relationships
| Hugh Calkins:DO have relevant financial relationships
;
Consultant:Atricure:Active (exists now)
; Consultant:Johnson and Johnson:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Consultant:Medtronic:Active (exists now)
| Cynthia James:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Lexeo Therapeutics:Active (exists now)
; Consultant:Lexeo Therapeutics:Past (completed)
; Consultant:Pfizer Inc:Past (completed)
; Research Funding (PI or named investigator):Tenaya Inc:Active (exists now)
; Research Funding (PI or named investigator):EicoSIS:Past (completed)
; Research Funding (PI or named investigator):StrideBio Inc:Past (completed)
; Research Funding (PI or named investigator):Arvada inc:Active (exists now)
| Andreas Barth:No Answer
| Marina Rieder:DO NOT have relevant financial relationships
| Steven Muller:DO NOT have relevant financial relationships
| Brittney Murray:DO NOT have relevant financial relationships
| Crystal Tichnell:No Answer
| Alessio Gasperetti:DO NOT have relevant financial relationships
| Richard Carrick:DO NOT have relevant financial relationships
| Anneline Te Riele:DO NOT have relevant financial relationships
| Emily Joseph:DO NOT have relevant financial relationships